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LETTER TO THE EDITOR
Fig. 1. Three month follow-ep showing improvement in psoriasis.
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Dear Editor: 
Interferon, an immunomodulator and antiproliferative with 
antiviral properties, has side effects that include flu-like 
symptoms, marrow suppression, alopecia and depression. 
Other side effects of interferon are rare skin reactions
1,2, 
namely erythematous patches at site of injection and 
eczema. Interferon may also induce or “unmask” under-
lying skin diseases such as psoriasis
3,4, eczema, sarcoidosis 
and lupus. The combination of interferon and ribavirin is the 
current treatment for hepatitis C. We present a patient with 
extensive psoriasis whose symptoms dramatically improved 
when she was treated with pegylated interferon and ribavirin 
for hepatitis C. 
A 52-year-old white female was referred to us for mana-
gement of chronic hepatitis C infection in April 2006. She 
had nonspecific symptoms. She also had hypertension, 
diabetes mellitus, mild rheumatoid arthritis, depression 
and obesity. Since age eight, she had had psoriasis 
involving multiple areas on her body. She expressed low 
esteem, secondary to the degree of psoriatic involvement 
and her obesity. She had no allergies. 
On examination, the patient was alert and had normal 
vital signs. HEENT (Head, Ears, Eyes, Nose and Throat), 
cardiopulmonary, abdomen, extremities and neurological 
examinations were normal. She had no lymphadenopathy. 
Skin examination was remarkable for extensive bilateral 
erytherodermic nodular lesions with plaques involving the 
extensor surfaces of elbows, forearms, thighs and knees. 
Lesions were more prominent on the left side. She also 
had scattered involvement over the abdomen, lower back 
and scalp. Approximately 15∼20% of her skin surface 
was covered with lesions (at this time, no photos were 
taken) (Table 1).
Medications included metformin, hydrochlorathiazide, 
loratadine and acetaminophen. She was using clobetasol 
cream topically. 
In June 2006, the patient was started on hepatitis C 
treatment with a combination of interferon alfa-2b (1.5 
mcg/kg/week subcutaneously) and ribavirin (1,200 mg) 
orally every day. In the third week following initiation of 
therapy, she complained of a skin rash and itching over 
the lower extremities, which subsequently spontaneously 
improved. An examination at that time showed diffuse, 
erythematous, maculopapular eruptions which was not 
psoriatic. She also had flu-like symptoms secondary to 
interferon. After three months, the patient complained of 
diarrhea, abdominal cramps and hair loss, but her psori-
asis had improved. Examination revealed definite improve-E Habte-Gabr and N Lecea
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Table 1. Laboratory studies
4/27/06 11/15/06 & 12/11/06 4/06/07 5/04/09 2/12/10
Initial visit: 
Tx begins 6/06
FU visits: 
5 and 6 mos.
FU visit: 
1 yr.
FU visit: 
3 yrs.
FU visit: 
3½ yrs
WBC 10
3/ u l       1 1 . 3        5 . 6        9 . 2       1 0 . 4        9 . 0
Differential counts  Normal  Normal  Normal  Normal  Normal
H b  ( g / d l )       1 5 . 8       1 4 . 0       1 5 . 0       1 6 . 3       1 4 . 4
H c t  ( % )       4 6 . 8       4 1 . 7       4 4 . 7       4 8 . 6       4 2 . 2
A l b u m i n  ( g / d l )        3 . 9        3 . 9        3 . 8        4 . 1
S G O T  ( A S T )  U / l         2 6       2 2       2 0       1 4       1 7
SGPT (ALT) U/l        44 (↑)       2 7       1 9       1 6       2 8
Alkaline phosphatase (U/l)      100       82      101       91       71
Bilirubin T/D mg/dl  0.4/0.1        0.5 0.6/0-1 0.3/0-1 0.3/0-1
TSH mU/l        1.42        1.80        1.64
Hep C RNA viral
 load per milliliter
6,036,990  Below level
  of detection
 Below level
  of detection
 Below level
  of detection
 Below level
  of detection
HIV antibody test   Negative 
Cryoglobulin test  Negative  Negative
Tx: treatment, FU: follow-up, WBC: white blood cell, Hb: hemoglobin, Hct: hematocrit, SGOT: serum glutamic oxacetic transaminase,
SGPT: serum glutamic pyruvic transaminase, AST: spartate minotransferase, ALT: alanine minotransferase, T/D: total/direct, TSH: thyroid
stimulating hormone, HIV: human immunodeficiency virus.
Fig. 2. After completion of interferon/
ribavirin therapy, examination showed
only a mild reactivation of the pso-
riatic lesions.
ment of her skin lesions with less erythema and scaling of 
the plaques on the elbows, knees and thighs (Fig. 1). There 
was also significant clearing of the lesions on the scalp, 
abdomen and back. Serum hepatitis C viral-RNA load 
decreased to an undetectable level. After the completion 
of six months interferon/ribavirin therapy, she has had no 
relapse of hepatitis C infection and only a mild reactiva-
tion of the psoriatic lesions (Fig. 2). During this time, she 
denied use of topical steroids or other psoriasis treatments.
Exacerbation of psoriasis following the use of interferon in 
the treatment of hepatitis has been reported
5,6. In fact, 
interferon is believed to be associated with the patho-Psoriasis and Hepatitis C: Improvement with Interferon
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genesis of psoriasis
5,7,8. Both hepatitis C and psoriasis are 
diseases in which tumornecrosis factor-α (TNF-alpha) is 
involved. 
During treatment with interferon/ribavirin, this patient’s 
psoriasis improved and has remained less active for 4＋ 
years following treatment. We have no definite expla-
nation for the significant improvement of psoriasis. The 
patient has been under no psoriatic treatment program 
during this time. Precipitating factors such as infection can 
activate T-cells and cytokine production, resulting in the 
release of inflammatory mediators that can flare psoriasis. 
In this patient, perhaps the active hepatitis C infection 
precipitated more dramatic psoriatic involvement. This 
hypothesis is supported by the significant decrease and 
subsequent disappearance of detectable serum load over 
the time her psoriasis has shown such significant improve-
ment. Further investigation is needed to show a direct 
causal relationship between the patient’s treatment with 
interferon/ribavirin and improved psoriasis through the 
decreased activation of T-cells and cytokine production. 
REFERENCES
1. Mistry N, Shapero J, Crawford RI. A review of adverse cuta-
neous drug reactions resulting from the use of interferon and 
ribavirin. Can J Gastroenterol 2009;23:677-683.
2. Asnis LA, Gaspari AA. Cutaneous reactions to recombinant 
cytokine therapy. J Am Acad Dermatol 1995;33:393-410.
3. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. 
Lancet 1986;1:1466-1468.
4. López-Lerma I, Iranzo P, Herrero C. New-onset psoriasis in a 
patient treated with interferon beta-1a. Br J Dermatol 2009; 
160:716-717.
5. Citro V, Fristachi R, Tarantino G. Extensive psoriasis induced 
by pegylated interferon: A case report. J Med Case Reports 
2007;1:86. 
6. Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced 
by interferon alfa treatment for chronic hepatitis C. Postgrad 
Med J 2000;76:365-367.
7. Downs AM, Dunnill MG. Exacerbation of psoriasis by inter-
feron-alpha therapy for hepatitis C. Clin Exp Dermatol 2000; 
25:351-352.
8. Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moula-
kakis A. Extensive psoriasis induced by pegylated interferon 
alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 
2005;15:107-109.